Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-12-10
DOI
10.1038/s41467-021-27312-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
- (2021) Stephan Kadauke et al. JOURNAL OF CLINICAL ONCOLOGY
- Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
- (2021) Dina Schneider et al. Science Translational Medicine
- Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
- (2020) Zachary Jackson et al. Frontiers in Immunology
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
- (2020) Qing Deng et al. NATURE MEDICINE
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
- (2020) Sri Krishna et al. SCIENCE
- Clinical lessons learned from the first leg of the CAR T cell journey
- (2019) Robbie G. Majzner et al. NATURE MEDICINE
- Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
- (2019) Rebecca A. Gardner et al. BLOOD
- Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
- (2018) Fenlu Zhu et al. CYTOTHERAPY
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
- (2018) Dina Schneider et al. Frontiers in Oncology
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
- (2017) James N. Kochenderfer et al. MOLECULAR THERAPY
- T memory stem cells in health and disease
- (2017) Luca Gattinoni et al. NATURE MEDICINE
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- The growing world of CAR T cell trials: a systematic review
- (2016) Astrid Holzinger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Lymphoblastic Leukemia in Children
- (2015) Stephen P. Hunger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
- (2014) Kieron Dunleavy et al. BLOOD
- Transformed follicular non-Hodgkin lymphoma
- (2014) Carla Casulo et al. BLOOD
- Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
- (2014) Laurie H. Sehn et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Interleukin-6 and its receptors: A highly regulated and dynamic system
- (2014) Janina Wolf et al. CYTOKINE
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cognition assessment using the NIH Toolbox
- (2013) S. Weintraub et al. NEUROLOGY
- Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia
- (2012) Martin Schrappe et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
- (2011) Ching-Hon Pui et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
- (2009) Richard H. Ko et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search